NR1H4 and metabolic dysfunction-associated steatohepatitis: The farnesoid X receptor (FXR) is a ligand-activated transcription factor, highly expressed in the liver and intestine, which has shown promising clinical results in the treatment of non-alcoholic steatohepatitis (NASH) [3,4,5].